Truist Securities reiterates Buy rating on argenx stock with $918 target

Argenx SE (NASDAQ:ARGX) has seen a surge in analyst confidence and price target increases, notably from Truist Securities which reiterated a Buy rating and $918 target, following positive clinical developments. The company presented promising preclinical and Phase 1b data for ARGX-119 in congenital myasthenic syndromes (CMS) and its advancement into an ALS trial, building on Vyvgart's recent success in a Phase 3 study for seronegative generalized myasthenia gravis. This robust pipeline performance, coupled with impressive 88% revenue growth, underscores growing institutional optimism regarding argenx's expanding market potential and strong investment profile.

Analysis

Analyst sentiment for argenx SE (ARGX) has turned decisively positive, supported by a series of significant clinical and financial proof points. A consensus of Buy-equivalent ratings has formed, with firms like Truist Securities, Piper Sandler, and BofA Securities issuing price targets ranging from $820 to $918. This optimism is directly linked to two core catalysts: the successful commercial drug Vyvgart and the promising pipeline asset ARGX-119. Vyvgart met its primary endpoint in a Phase 3 study for seronegative generalized myasthenia gravis (gMG), expanding its market potential. Simultaneously, the company's R&D event showcased strong clinical proof-of-concept for ARGX-119 in congenital myasthenic syndromes (CMS) and its advancement into a clinical trial for amyotrophic lateral sclerosis (ALS), with topline results for the latter expected in H1 2026. This pipeline momentum is substantiated by the company's robust financial health, highlighted by an 88% revenue growth rate and strong liquidity, reinforcing the thesis that argenx is successfully translating clinical progress into fundamental value.

Key Decisions for Investors

• Given the strong positive analyst consensus and price targets north of $900, investors with existing positions could view these updates as a strong validation of the company's growth platform and pipeline.
• Potential investors should note the key upcoming catalysts, specifically the progress of Phase 3 trials for ARGX-119 in CMS and the topline data from the ALS trial in H1 2026, as these events are critical for sustaining valuation momentum.
• Evaluate the current share price relative to the new cluster of analyst price targets ($778-$918) to assess the remaining upside, as the recent wave of positive news is likely becoming priced into the stock.